AECOPD
Conditions
Interventions
Medium dosage granule group (75% of the standard dosage):On the basis of conventional Western medical treatment add medium dosage (75% of the standard dosage) formula granules.
Traditional decoction pieces group:On the basis of conventional Western medical treatment an additional Chinese herbal decoction (Xiao Qing Long Jia Xing Ren Shi Gao Tang) is administered.
Same-price granule group (33% of the standard dosage):On the basis of conventional Western medical treatment add formula granules priced equivalent to the Chinese herbal decoction (Minor Blue Dragon D
Placebo group:On the basis of conventional Western medical treatment add a placebo of Chinese herbal formula granules.
Standard dosage granule group:On the basis of conventional Western medical treatment add formula granules equivalent in dosage to the Chinese herbal decoction pieces (Xiao Qing Long Jia Xing Ren Shi G
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age between 40 and 80 years; (2) Meets the diagnostic criteria for the aforementioned AECOPD (without respiratory failure); (3) Requires hospitalization and is admitted within 48 hours of onset; (4) Breathlessness Cough and Sputum Scale (BCSS) score of =6 upon admission; (5) Signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Shock or other hemodynamic instability; (2) Requires mechanical ventilation; (3) Concurrent active pulmonary tuberculosis lung cancer (confirmed or suspected) lung abscess; (4) Concurrent severe pulmonary organic lesions (e.g. severe bronchiectasis severe pulmonary fibrosis/cystic fibrosis/interstitial disease severe pulmonary hypertension severe obliterative bronchiolitis etc.) or other active pulmonary diseases; (5) History of lung resection or lung volume reduction surgery in the past 12 months; (6) Undergoing pulmonary rehabilitation during the study; (7) Severe heart disease history such as acute myocardial infarction congestive heart failure (NYHA class III and above) severe arrhythmia and other acute cardiac diseases; (8) Severe primary diseases of important organs and systems such as acute stroke poorly controlled hypertension active peptic ulcer diabetes (with severe complications) malignant tumors etc.; (9) Active hepatitis A hepatitis B HIV tuberculosis and infectious connective
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SRT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary function indicators at 30 90 and 180 days (FVC FEV1 FEV1/FVC);Days without hospitalization within 30 90 and 180 days;Day 11 30 90 and 180 BCSS scores;Length of hospital stay and ICU stay duration;6-minute walk test (6MWT);Number of days between discharge and the next acute exacerbation;Number of acute exacerbation recurrences within 180 days;Time not taking traditional Chinese medicine during the first hospitalization; | — |
Countries
China
Contacts
Public Contactgao peiyang
Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed